MAPT and Alzheimer disease: Interestingly, the presence of these epitopes in CSF (e.g., p181) distinguishes between AD and non-AD pathology, and thus, phosphorylated tau released from neurons into CSF can be a predictor of progressive cognitive impairment and presymptomatic patients (42, 44, 45).